含肺炎球菌蛋白的肺炎球菌结合疫苗配方免疫原性及同时接种常规疫苗的免疫原性与反应原性:冈比亚婴儿II期随机观察者盲法研究
该II期随机观察者盲法研究在冈比亚8-10周龄健康婴儿中评估含dPly和PhtD的PHiD-CV/dPly/PhtD配方的多糖结合物免疫原性,以及同时接种常规疫苗的免疫原性与反应原性。共入组1200名婴儿,1152名完成研究。结果显示加入dPly和PhtD未改变对10种PHiD-CV多糖结合物及同时接种疫苗的免疫应答。
要点
- 加入dPly和PhtD未改变对10种PHiD-CV多糖结合物的免疫应答。
- 同时接种DTPw-HBV/Hib、OPV、麻疹和黄热病疫苗的免疫应答未受肺炎球菌蛋白影响。
- 同时接种疫苗的反应原性组间可比,未引起担忧。
核心结论
- 加入dPly和PhtD未改变对10种PHiD-CV多糖结合物及同时接种疫苗的免疫应答。
研究设计与样本
- II期、对照、观察者盲法、单中心研究,1200名8-10周龄健康婴儿随机(1:1:1:1:1:1)分六组。
- 四组采用3+0程序(2-3-4月龄)接种PHiD-CV/dPly/PhtD(每种蛋白10或30 μg)、PHiD-CV或13价肺炎球菌结合疫苗。
- 两组采用2+1程序(2-4-9月龄)接种PHiD-CV/dPly/PhtD(每种蛋白30 μg)或PHiD-CV。
- 所有婴儿在2-3-4月龄接种DTPw-HBV/Hib和OPV,9月龄接种麻疹、黄热病和OPV疫苗。
- 1152名完成研究,评估2-5-9-12月龄免疫应答及接种后0-3天反应原性。
主要发现
- 基础免疫后1个月,除6B和23F外,各PHiD-CV血清型≥97.4%(3+0程序)和≥96.4%(2+1程序)婴儿抗体浓度≥0.2 μg/mL。
- 同一接种程序内组间免疫应答可比。
- 基础免疫后1个月观察到的抗体几何平均浓度(GMC)较接种前升高。
- 随后数月GMC和调理吞噬活性滴度下降,2+1程序加强后升高。
- 对蛋白D及DTPw-HBV/Hib、OPV、麻疹、黄热病疫苗的免疫应答未因同时接种肺炎球菌蛋白而改变。
临床怎么用
- 含dPly和PhtD的PHiD-CV配方未干扰多糖结合物及常规疫苗免疫应答,支持进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two conserved pneumococcal proteins, pneumolysin toxoid (dPly) and pneumococcal histidine triad protein D (PhtD), combined with 10 polysaccharide conjugates from the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) in two investigational pneumococcal vaccine (PHiD-CV/dPly/PhtD) formulations were immunogenic and well-tolerated when administered to Gambian children. Here, we report immunogenicity of the polysaccharide conjugates, and immunogenicity and reactogenicity of co-administered routine vaccines. METHODS: In this phase II, controlled, observer-blind, single-centre study, healthy infants aged 8-10 weeks were randomised (1:1:1:1:1:1) to six groups. Four groups received 3+0 schedule (2-3-4 months [M]) of PHiD-CV/dPly/PhtD (10 or 30 µg of each protein), PHiD-CV, or 13-valent pneumococcal conjugate vaccine; and two groups received 2+1 schedule (2-4-9 M) of PHiD-CV/dPly/PhtD (30 µg of each protein) or PHiD-CV. All infants received diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b (DTPw-HBV/Hib) and oral trivalent polio vaccines (OPV) at 2-3-4 M, and measles, yellow fever, and OPV vaccines at 9 M. We evaluated immune responses at 2-5-9-12 M; and reactogenicity 0-3 days post-vaccination. RESULTS: 1200 infants were enrolled between June 2011 and May 2012; 1152 completed the study. 1 M post-primary vaccination, for each PHiD-CV serotype except 6B and 23F, ≥97.4% (3+0 schedule) and ≥96.4% (2+1 schedule) of infants had antibody concentrations ≥0.2 μg/mL. Immune responses were comparable between groups within the same vaccination schedules. Observed antibody geometric mean concentrations (GMCs) increased by 1 M post-primary vaccination compared to pre-vaccination. In the following months, GMCs and opsonophagocytic activity titres waned, with an increase post-booster for the 2+1 schedule. Immune responses to protein D and, DTPw-HBV/Hib, OPV, measles, and yellow fever vaccines were not altered by co-administration with pneumococcal proteins. Reactogenicity of co-administered vaccines was comparable between groups and did not raise concerns. CONCLUSION: Immune responses to the 10 PHiD-CV polysaccharide conjugates and co-administered vaccines were not altered by addition of dPly and PhtD. ClinicalTrials.gov identifier NCT01262872.
引用
- Odutola A, Ota MOC, Antonio M, et al. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants. Vaccine. 2019. PMID: 30975570. doi:10.1016/j.vaccine.2019.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。